2 active not recruiting, 2 completed, 1 not yet recruiting, 1 terminated. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Active not recruiting 2, Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Glioblastoma: new trials by email Literature Review of Glioblastoma trials Research Report on Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Zoster Vaccination in Glioblastoma Patients Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM) | Phase 4 | Not yet recruiting | University Hospital, Essen | 230 | 2027-01-02 | 2026-04-23 |
| Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy - Glioblastoma | Phase 4 | Withdrawn | GT Medical Technologies, Inc. | 2025-05-01 | 2025-04-10 | |
| Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma | Phase 4 | Completed | Mayo Clinic | 30 | 2024-10-07 | 2026-04-29 |
| GammaTile and Stupp in Newly Diagnosed GBM Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide) - Glioblastoma | Phase 4 | Active not recruiting | GT Medical Technologies, Inc. | 61 | 2022-08-17 | 2025-09-05 |
| The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab Pembrolizumab - Newly Diagnosed Glioblastoma | Phase 4 | Unknown | Medical University of Silesia | 36 | 2022-03-01 | 2023-08-31 |
| Pediatric Long-Term Follow-up and Rollover Study dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 163 | 2019-11-04 | 2026-08-27 |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients NovoTTF-100A - Recurrent Glioblastoma Multiforme | Phase 4 | Terminated | NovoCure Ltd. | 13 | 2012-12-01 | 2016-03-02 |
| Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Temozolomide, Radiotherapy - Glioblastoma | Phase 4 | Completed | Merck Sharp & Dohme LLC | 99 | 2008-06-24 | 2017-06-14 |
Glioma (3) · Astrocytoma (2) · Neoplasms (2) · Oligodendroglioma (2) · Recurrence (2) · Brain Neoplasms (1) · Ganglioglioma (1) · Ganglioneuroma (1) · Histiocytosis, Langerhans-Cell (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Neurocytoma (1) · Neurofibroma, Plexiform (1) · Neurofibromatosis 1 (1)
Neoplasms by Histologic Type (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Nerve Tissue (8) · Neoplasms, Neuroepithelial (8) · Neuroectodermal Tumors (8) · Astrocytoma (6) · Neoplasms (6) · Glioma (5) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Disease Attributes (2) · Neoplasms by Site (2) · Nervous System Diseases (2)
Temozolomide (2) · Observational Studies as Topic (1) · Outcome Assessment, Health Care (1) · Radiation (1) · Radiosurgery (1) · Radiotherapy (1) · Restraint, Physical (1) · dabrafenib (1) · pembrolizumab (1) · trametinib (1)
GT Medical Technologies, Inc. (2) · Mayo Clinic (1) · Medical University of Silesia (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · NovoCure Ltd. (1) · University Hospital, Essen (1)
United States (4) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Herbert Engelhard, MD, PhD (1) · Tufia C. Haddad, MD (1) · Ugur T. Sener, MD (1)
PMID 26481741, PMID 36239858, PMID 41567708
2023 (1)